With Hemlibra, Roche Seeks to Break Into Tight Hemophilia Circle

By REUTERS
NYT
Swiss drugmaker Roche is breaking into hemophilia A treatment, a $10 billion (£7.70 billion) global market dominated by rivals who have cultivated close ties to sufferers of the genetic bleeding disorder.
Published date: October 3, 2018 at 09:04AM
Reuters
New York Times article